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5THE SECRET OF DYING WELL: THE MANY 
FACES OF CELL DEATH AND ITS RELEVANCE 
FOR TREATING DISEASES OF OUR TIME
PROGRAMMED CELL DEATH
Morphological investigations of cell death quickly revealed 
that there is more than one way to die. Besides apoptosis 
and necrosis, autophagy has emerged within the field of cell 
death, each exhibiting distinct morphological characteristics. 
Apoptosis (type I cell death) is characterised by distinct 
morphological changes in the cell. The physical process 
begins with the detachment and shrinkage of the 
apoptotic-competent cell.3 This is followed by nuclear 
chromatin condensation (pyknosis) and its degeneration 
into internucleosomal fragments (karyorrhexis) by 
endonucleases to produce the classic DNA-laddering 
pattern. Subsequently, permeabilisation and blebbing of the 
plasma membrane gives rise to discrete apoptotic bodies. 
A membrane phospholipid termed phosphatidylserine (PS), 
typically contained within the inner plasma membrane, 
becomes exposed to the outer membrane surface during 
the morphological transformation.4 The process culminates 
in the recognition of these apoptotic-competent cells by 
phagocytes which proceed to engulf the apoptotic bodies 
in a rapid, yet irreversible manner.5 The externalised PS 
lipids aid in the recognition of the apoptotic bodies and 
their subsequent phagocytosis.6 Clearance occurs without 
invoking an inflammatory response.7
While apoptosis is characterised by an active participation 
of the affected cell in its own demise, necrosis, on the other 
hand, is a passive, catabolic and degenerative process (see 
Figure 1). Necrosis generally represents a cell’s response to 
gross injury and can be induced, for example by exposure 
to an overdose of cytotoxic stimuli. The early events of 
necrosis are mitochondrial swelling followed by rupture 
of the plasma membrane and release of cytoplasmic 
constituents, which include proteolytic enzymes.8,9 Nuclear 
chromatin shows patchy areas of condensation and the 
nucleus undergoes slow dissolution (karyolysis). Necrosis 
triggers an inflammatory reaction in the tissue and often 
results in scar formation. 
The dynamic nature of life becomes more and more apparent with every advance in scientific understanding. It is said that 
the beauty of science lies in the simplicity of its purpose: the search for truth. As Keats so aptly put it in his Ode on a Grecian 
urn: ‘Beauty is truth, truth beauty’ – that is all ye know on earth, and all ye need to know”.
The French physiologist Claude Bernard (1813–1878), regarded as the father of modern physiology, observed that the 
milieu interieur (internal environment) of the body remains remarkably constant despite changing conditions in the external 
environment. In his book, entitled The wisdom of the body, and published in 1932, Walter Cannon was the first to coin the term 
‘homeostasis’ to describe this constant internal environment. He suggested that many mechanisms of physiological regulation 
have but one purpose – to maintain this internal constancy in the human body. Cells, the fundamental building blocks of the 
human body, maintain the existence of life as thousands of intricate pathways and masses of information are rapidly processed 
in these 4–135 mm units to maintain homeostasis.1 The body consists of trillions of cells – about 100 000 cells are produced 
every second. To counterbalance this proliferation, a similar number die every second.2 This homeostasis is tightly controlled 
by programmed cell death, which is a ubiquitous process essential for cellular turnover. When this system is disrupted, even 
slightly, various disease states, including heart disease and cancer, can ensue.
6lacks the characteristic vesicular formation and rather 
employs the use of cytosolic chaperones which selectively 
recognise and translocate proteins. Micro-autophagy and 
macro-autophagy (referred to generally as autophagy) are 
the other two forms of autophagy, characterised by the 
formation of vesicles which allow for the degradation of 
cytosol, proteins and/or organelles.17 While the former 
entails the direct sequestration and degradation of cargo by 
lysosomal membrane invaginations, the latter necessitates 
the vacuolisation of cargo within double-membraned 
structures, termed the autophagosomes, prior to fusion 
with the lysosome.
1) INDUCTION 2) NUCLEATION 3) ELONGATION 4) COMPLETION 5) MATURATION 6) DEGRADATION
Phagophore
Autophagosome
Autophagolysosome
Figure 2: Schematic representation of the morphological and
molecular mechanisms involved in autophagic biogenesis. The
inactivation of mTOR promotes the formation of the ULK1-Atg13-Atg17
complex, which subsequently associates with the isolation
membrane/phagophore (1). The successive association of Beclin 1 and
UVRAG in a complex stimulates Vps34 activity to initiate the formation of
autophagosomes (“nucleation”) (2). Two ubiquitin-like conjugation
systems lead to the formation of the Atg12-Atg5 conjugate and the
Lipidated
LC3-II
Autophagic cargo
lipidated phosphatidylethanolamine (PE)-associated LC3-II conjugate, both of which promote elongation (3). The LC3-II conjugate becomes
incorporated into the membranes of the developing autophagosome. Upon completion (4), the maturation phase follows with the fusion of the
autophagosome with a lysosome to form an autophagolysosome (5). The encapsulated cargo, as well as the inner limiting membrane, becomes
degraded by acid lysosomal hydrolyases (6).
MSc Thesis: Justin Mills (2013)
Fusion
Lysosome
The execution process of autophagy (see Figure 2) begins 
within the cytoplasm with the formation of crescent-
like membranous structures termed phagophores, or 
isolation membranes.18 This is the initiation stage of the 
autophagic process. During the elongation stage which 
follows, these specialised structures expand into double- 
or multi-membraned autophagosomes, also known as 
early autophagic vesicles, which sequester cytosol or 
cellular components for ‘bulk’ degradation. The cargo may 
be targeted selectively or non-selectively.15 The outer 
autophagosomal membrane first fuses with an endosomal 
vesicle to form an amphisome.18 This is followed by 
fusion with a lysosome to form an autophagolysosome, 
also known as a late autophagic vesicle. Acid hydrolases 
within the lysosome digest the inner membrane of the 
autophagosome along with its encapsulated luminal cargo. 
These hydrolases include nucleases, proteases, glycosidases 
and lipases, enabling a broad range of macromolecules to be 
degraded simultaneously.12,19
The many different types of cell death pathways contain 
a multitude of different biochemical components, many 
of which are not yet understood. As these pathways are 
more or less sequential in nature, removing or modifying 
one component leads to an effect in another. In a living 
organism, this can have disastrous effects, often in the form 
of disease or disorder.  A discussion of every disease caused 
by modification of the various cell death pathways would 
be impractical, but the concept overlying each one is the 
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Figure 1: Morphological characteristics of a necrotic and an 
apoptotic cell
The pattern of cell death may not always have the classical 
features of either apoptosis or necrosis. Numerous 
examples of cell death have been described in which the 
morphological and/or biochemical changes resembled 
neither typical apoptosis nor necrosis, but often had 
features of both.10,11 In some cases, the integrity of the 
plasma membrane was preserved but DNA degradation was 
random, without evidence of internucleosomal cleavage. In 
other situations, DNA degradation was typical of apoptosis 
but nuclear fragmentation and other features of apoptosis 
were not apparent.
Autophagy is defined as a cellular process of self-
degradation that is evolutionary conserved amongst 
species.12 It occurs constitutively at base-line levels within 
the cell to ensure homeostasis by removing aged, damaged 
or accumulated proteins and/or organelles. Beyond its 
quality control function, the autophagic process can also 
be massively augmented in response to various intracellular 
and extracellular stress stimuli.13 These include nutrient 
and growth factor deprivation (metabolic stress), radiation 
and chemotherapy (DNA damage), endoplasmic reticulum 
(ERt) stress, hypoxia and viral invasion. During starvation 
conditions, cellular metabolism and biosynthesis can be 
sustained from the recycled pool of cytosolic biomolecules 
generated during autophagy.14 Elimination of excessive 
reactive oxygen species produced by mitochondria under 
hypoxia, as well as unfolded or aggregated proteins may 
prevent these forms of ‘cellular garbage’ from potentially 
inducing carcinogenesis. While short-lived proteins are 
degraded by the ubiquitin proteasome pathway, long-lived 
proteins are mitigated by autophagy.15
Depending on the mechanism by which the cytosolic 
cargo is delivered to lysosomes for degradation, three 
different types of autophagy exist. Chaperone-mediated 
autophagy mediates the direct translocation of a single 
cytosolic protein, possessing a specific sequence motif, to 
the lysosome for degradation.16 This form of autophagy 
7same: The normal functioning of the pathway has been 
disrupted in such a way that the ability of the cell to die 
normally is impaired. This results in cells that replicate and 
pass on faulty genetic information to its progeny, increasing 
the likelihood of the cells becoming cancerous or diseased. 
The interaction of genetics, the environment and nurture is 
the foundation for all health and disease, therefore nutrition 
is an environmental factor of major importance. Using the 
tools of molecular biology and specifically to understand 
the factors which induce or inhibit cell death, the aim of our 
research is to unravel the signalling mechanisms induced by 
environmental/nutritional factors and to exploit the cell’s 
own machinery to search for new and safe therapeutic 
modalities.
THE SEARCH FOR NEW AND SAFE 
THERAPEUTIC STRATEGIES
OMEGA-3 FATTY ACIDS: NATURE’S OWN 
THERAPY? 
The notion that fatty acid intake may influence the incidence 
of cancer and heart disease has been studied intensively in 
vivo and in vitro for more than 40 years and seems to be 
widely accepted. Ranging from epidemiological studies to 
those conducted using cell culture models, most studies 
provide evidence that omega-3 (n-3) fatty acids, especially 
the long-chain polyunsaturated fatty acids (PUFAs) 
eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), found abundantly in fish oil, are able to inhibit the 
development of cancer or slow down tumour growth.20,21 
However, the cellular mechanisms responsible for these 
effects have not yet been clarified, although various 
hypotheses exist, including modifications to eicosanoid 
metabolism and activation of different cellular signalling 
pathways.22,23  
Epidemiological evidence for a link between diet, 
cancer incidence and heart disease
Epidemiological studies have demonstrated a lower incidence 
of certain malignancies amongst certain populations. This 
phenomenon was most notably described in the Inuit 
population of Greenland24–27 and a related phenomenon 
was also seen in Mediterranean countries, where olive oil 
(composed mainly of oleic acid) is an important part of the 
diet.28–31 The typical Greenland Eskimo diet is high in lipids, 
contains predominantly large quantities of seal and fish and 
is rich in omega-3 fatty acids.32,33 When the plasma lipids of 
native Greenland Eskimos were analysed and compared to 
that of Danes, the native Eskimos had higher plasma lipid 
concentrations of alpha-linolenic acid (ALA), EPA and DHA 
of the n-3 series.34 Yet as time passed the cancer profile 
of these populations changed markedly to resemble that 
of the American Caucasian population,26,27 which might be 
due to the adaptation of a Western lifestyle. Nonetheless, 
those early studies of the dietary habits of the Greenland 
inhabitants and the once rarity of cancer amongst them 
led to the first suggestions of the possible anticarcinogenic 
effects of PUFAs. 
During this time, much attention was also given to the 
proposal that such a plasma lipid profile was favourable 
towards a decreased incidence of atherosclerosis and 
ischaemic heart disease.34,35 
The n-6/n-3 imbalance
Since that time, it has become known that n-3 fatty acids are 
protective against a host of diseases such as cardiovascular 
disease (CVD), inflammation, neurodegenerative diseases 
and especially cancer.36 However, the typical Western diet 
consumed today is deficient in these important PUFAs, 
resulting in an increased risk for modern diseases such as 
those mentioned previously. In addition to the apparent n-3 
PUFA deficiency, the Western diet has elevated n-6 PUFA 
content, especially Linoleic Acid (LA) and Arachidonic 
Acid (AA).36,37 It is believed that the foods available to 
our ancestors (before agricultural practices and animal 
domestication were taken on) were rich in n-3 PUFAs and 
contained them in a ratio with n-6 PUFAs of approximately 
1:1. Such a fatty acid profile in food led the human body 
to establish a genetic pattern without genes that would 
enable it to synthesise fatty acids or convert them to 
another form. The n-6:n-3 PUFA ratio has increased over 
time, as the Western diet today contains a ratio of 15–20:1. 
Unfortunately, the human body cannot adjust its genome to 
suit such a lipid profile in such a short time, making modern 
man susceptible to devastating modern disorders. It is thus 
necessary to supplement our diets to enrich tissues with 
n-3 fatty acids and correct for the n-6/n-3 imbalance. 
The role of fatty acids as constituents of membrane 
phospholipids in normal and tumour cells
The fatty acids contained in membrane phospholipids are 
essential in determining certain physical properties of a 
membrane, such as fluidity and flexibility. They also regulate 
cellular functions, including the movement of ions and 
metabolic products across the membrane, receptor binding 
and eicosanoid production.38 Mammalian cells in vitro 
readily take up lipids such as fatty acids from their culture 
medium.39 Supplementation of media with different fatty 
acids is thus a simple method to manipulate the fatty acid 
composition of membrane phospholipids in cultured cells. 
When membrane phospholipid composition is modified, 
so are various cellular processes and responses. These 
include carrier-mediated transport, activities of membrane-
bound enzymes, binding properties of membrane receptors, 
cytotoxicity, growth, modulation of cellular signalling events, 
and eicosanoid synthesis, amongst others.36,38,39
The role of omega-3 fatty acids in the regulation of 
signalling pathways to induce cell death in cancer cells
Cancer is often described as a disorder of the balance 
between cell proliferation and cell death.40 During the 
progression of cancer, the tumour cells acquire a variety of 
phenotypic properties that allow them to proliferate both 
swiftly and limitlessly, invade the surrounding tissues, survive 
without their normal microenvironment, and metastasise.41 
8These features are usually acquired progressively over a 
protracted period of time as a result of increased genomic 
instability that leads to down-regulation of tumour 
suppressor genes and up-regulation of oncogenes.42 One 
such oncogene encodes the serine/threonine kinase Akt, 
also known as protein kinase B (PKB) (a member of the 
PI3-K pathway) and has emerged as a crucial regulator of 
widely divergent cellular processes, including apoptosis, cell 
proliferation, differentiation and metabolism.43–46 Disruption 
of normal PI3-K signalling has been documented as a 
frequent occurrence in several human cancers and appears 
to play an important role in their progression.37,47–48 The 
PI3-K signalling pathway should therefore be considered as 
a potential target for chemotherapy. 
In order for a therapeutic agent to be truly effective, it should 
be toxic to cancer cells without harming normal cells. It has 
been demonstrated both in animal and cell culture models 
that PUFAs can significantly reduce tumour size in vivo and 
suppress cell viability and induce apoptosis of cancer cells in 
vitro.49-52 However, the molecular mechanisms involved in the 
cytotoxic effect of PUFAs on cancer cells and the intracellular 
mechanisms responsible remain to be elucidated. Therefore, 
in order to assess the signalling mechanisms involved in 
the cytotoxic effect of PUFAs, we treated CaCo-2 (colon 
cancer) and NCM460 (normal colon epithelial) cells with 
a saturated (palmitic acid, PMA), a monounsaturated (oleic 
acid, OA) and two polyunsaturated fatty acids (arachidonic 
acid,  ARA, omega-6; docosahexaenoic acid, DHA, omega-3) 
and determined their effects on cell viability, apoptosis and 
protein phosphorylation events in the PI3-K pathway. This 
study was undertaken to evaluate the chemopreventive/
antiproliferative potential of saturated, monounsaturated, 
and polyunsaturated (omega-6 and omega-3) fatty acids on 
a colon cancer cell line and to investigate their mechanism 
of action. 
The fatty acid composition of membrane phospholipids can 
influence the function of certain membrane proteins, such as 
receptors, transporters and enzymes. Such changes would 
also have downstream signalling effects and could ultimately 
change the profile of gene expression. The fatty acids were 
differentially incorporated in the cell membranes of the 
cancer and the normal epithelial cells. In normal NCM460 
cells, DHA induced a three-fold increase in the phospholipid 
content and was also further b-oxidised to EPA. Our results 
demonstrated a much better incorporation of added 
fatty acids into NCM460 cells’ membrane phospholipids 
compared to CaCo-2 cells. This also might play a role in the 
dual effect of these fatty acids in normal versus cancer cells. 
Furthermore, when the total saturated, monounsaturated 
and polyunsaturated fatty acids in NCM460 and CaCo-2 
cells were compared, a two-fold increase in the omega-3 
fatty acid content was observed in normal cells compared 
to cancer cells. The reduced omega-3 fatty acid content in 
control CaCo-2 cells versus control NCM460 cells might 
thus explain the beneficial effect of DHA (an omega-3 fatty 
acid) when treating cancer cells.
The enrichment of tumour cell membranes with fatty acids 
has important therapeutic potential and has also been 
shown to enhance the cytotoxicity of therapeutic agents. 
Therefore, the next aim of this study was to determine 
the cytotoxic potential of various fatty acids on CaCo-
2 cells and normal colon epithelial cells (NCM460 cells). 
None of the fatty acids used in the current study were 
toxic to normal colon epithelial cells, but had differential 
effects on the cancer cells. DHA was the only fatty acid 
that significantly reduced the viability of the CaCo-2 cells. 
Although many mechanisms have been proposed to explain 
the tumour suppressive effects of these fatty acids, the 
molecular signalling mechanisms are still poorly elucidated. 
Therefore, the third aim of this study was to determine 
the effects of DHA on the PI3-K signalling pathway (see 
Figure 3). PI3-K is an essential part of the signalling network 
that blocks programmed cell death (apoptosis) and enables 
cells to survive when they are in a favourable environment. 
These pathways are activated so that a continuous survival 
signal from growth factors is required to block apoptosis.53 
Upon growth factor activation of receptor tyrosine kinases, 
PI3-K is recruited to the receptor in the plasma membrane 
and phosphorylates phosphatidylinositol-4,5-bisphosphate 
(PIP2) on the 3-OH group, generating phosphatidylinositol-
3,4,5-trisphosphate (PIP3). PI3-kinases are composed of 
a catalytic subunit (p110) and a regulatory subunit (p85). 
DHA and AA significantly reduced the regulatory subunit 
(p85), while no differences were observed in the catalytic 
subunit of PI3-K with any of the fatty acids. The decreased 
PI3-K level induced by DHA also correlates with increased 
apoptosis in our cell model. PI3-K is considered one of the 
intracellular pathways responsible for the transmission of 
anti-apoptotic signals for controlling cell survival and over-
expression of PI3-K in cells has been shown to cause a 
significant increase in survival of cells exposed to ionising 
radiation.54 We have demonstrated that DHA treatment 
inactivates PKB to decrease pro-apoptotic factors, which 
include BAD and Forkhead kinase (FKHR) phosphorylation. 
This, in turn, leads to increased apoptosis as indicated by 
increased caspase-3 and poly-ADP-ribose polymerase 
(PARP) cleavage. Our results confirmed the antiproliferative 
and antitumourigenic efficacy of DHA in colon cancer cells, 
together with its safety regarding normal colon epithelial 
cells. Although this study proposes one possible pathway 
for DHA’s effect on cell viability, the PI3-kinase signalling 
pathway and apoptosis, many other possible modes of 
action undoubtedly exist. 
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Figure 3: DHA inhibits pro-survival pathways and induces 
apoptosis in colon cancer cells (MSc thesis: J-L du Toit-Kohn, 2006)
OMEGA-3 FATTY ACIDS AND HEART 
DISEASE
Coronary heart disease (CHD) remains one of the leading 
causes of death in all Western industrialised countries. 
Although epidemiology and human intervention trials 
consistently show an inverse relationship between dietary 
omega-3 fatty acid consumption and mortality from 
heart disease55–57 the mechanism of action of these fatty 
acids remains to be elucidated. Long-chain PUFAs play an 
important role in various biological processes in cardiac 
muscle cells. PUFAs can either act as second messengers or 
as reversible modulators to amplify, attenuate or deviate a 
signal at a precise intracellular location.58
Previous studies have shown that a variety of extracellular 
stimuli, including ischaemia-reperfusion, profoundly affect the 
activation of the mitogen-activated protein kinases (MAPKs), 
which includes extracellular signal-regulated protein kinase 
(ERK), p38 and c-Jun NH2-terminal protein kinase (JNK).
59-
62 All three MAPKs have been shown to play pivotal roles 
in transmission of signals from cell surface receptors to 
the nucleus and are involved in cell growth, differentiation 
and apoptosis.63-65 In response to MAPK activation, a family 
of dual-specificity phosphatases becomes transcriptionally 
induced, leading to dephosphorylation and inactivation of 
specific MAPKs within 30 to 60 minutes.66 Currently ≈9 
dual-specificity phosphatase family members have been 
described, each of which has a slightly different substrate 
specificity, tissue distribution, subcellular localisation or 
inducible expression profile.66 MKP-1 (mitogen-activated 
protein kinase phosphatase-1) is an important member of 
this family, which regulates inactivation of p38, JNK and ERK. 
67-69 However, no evidence existed for an interaction between 
EPA and the activation/inhibition of the MAPKs and the 
pro-survival kinase PKB/Akt in neonatal rat cardiomyocytes 
during simulated ischaemia (SI) and reperfusion. Therefore, 
in order to assess the mechanisms of protection of long-
chain PUFAs in injured/apoptotic heart cells, we treated 
neonatal cardiomyocytes with EPA prior to and after 
simulated ischaemia and determined their effects on cell 
viability, apoptosis and the activation patterns of the MAPKs 
and PKB/Akt. To further evaluate the significance of findings 
obtained in a cell model of simulated ischaemia, the effect 
of the PUFAs on functional recovery of isolated globally 
ischaemic perfused rat hearts was also studied.
Our results have shown that EPA protects cardiomyocytes 
against simulated ischaemia-reperfusion injury. It is 
suggested that their beneficial actions are due to: (i) the 
increased phosphorylation of ERK which is PKC-dependent, 
(ii) the induction of a tyrosine phosphatase, leading to the 
reduced phosphorylation of the pro-apoptotic p38, and (iii) 
the activation of an as yet unknown pathway distal to PI3-K. 
Both increased ERK phosphorylation and the inhibition of 
p38 phosphorylation may contribute to the increased cell 
viability and decrease in apoptosis induced by EPA. Finally, 
the increased cell viability and reduced apoptosis induced 
by EPA studied in this cell model were also reflected by 
the significant improvement in functional recovery of the 
globally ischaemic heart during reperfusion. Thus, EPA 
might offer an alternative, non-pharmacological strategy to 
protect the heart against ischaemia-reperfusion injury.
AUTOPHAGY AND CHEMOTHERAPY: 
EXPLOITING THE CELL’S OWN 
MACHINERY AS ADJUVANT THERAPY
Anthracyclines, such as doxorubicin (DXR), are considered 
as some of the most effective chemotherapeutic agents 
for the treatment of breast cancer.70 Unfortunately, 
anthracyclines are also cytotoxic and affect a wide variety of 
systems. Progressive myocardial damage and skeletal muscle 
atrophy are possible results of their cumulative effect.71 As 
the cardio- and muscle toxicity of these drugs is cumulative 
and dose-limiting, methods for inducing cell death at earlier 
time points in the treatment regime are urgently needed. 
However, this is not the only challenge that researchers and 
clinicians are faced with. Despite the fact that DXR induces 
damaging effects on the heart, cancer cells are becoming 
inherently resistant to DXR-induced cell death.
Chemo-resistance
The resistance of cancer cells to chemotherapy (chemo-
resistance) is a multifaceted challenge faced by oncologists 
and their cancer patients. Initially, patients are susceptible to 
chemotherapy (chemo-sensitive) and cancer free directly 
after their course of treatment. However, 50% to 70% of 
patients relapse within one year as a result of poor surgical 
outcomes in which whole tumours are not completely 
resected, subsequently leading to the formation of another 
tumour. 
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The micro-environment (stroma) consists of endothelial 
cells, carcinoma-associated fibroblasts, adipocytes, 
mesenchymal cells, mesenchymal stem cells and cells from 
the immune and inflammatory systems. As these stromal 
cells communicate with each other,72 accumulating evidence 
shows that the cells residing in this niche could potentially 
induce chemo-resistance in tumour cells by influencing 
cancer cell sensitivity to apoptosis; local release of soluble 
factors such as interleukin-6 (IL-6) that promote survival; 
the generation of specific niches within the tumour micro-
environment which consist of subpopulations of tumour 
cells that may gain a survival advantage following initial 
drug exposure; and the conversion of the cancer cells into 
cancer-initiating cells or cancer stem cells. Although the 
cross-talk between the stromal cells and tumour cells are 
crucial in developing tumours, cells located in the intra-
tumour, avascular regions face other challenges posed 
by this niche. This specific region is characterised by low 
nutrients and oxygen (hypoxia), acidic extracellular pH and 
populations of quiescent cells which subsequently impact 
on the success of chemotherapy in solid tumours.73 The 
rapid rate of tumour growth requires increased levels of 
energy production through cellular metabolism. However, 
inadequate vascularisation progressively leads to a hypoxic 
tumour environment. The hypoxic environment requires that 
energy demands are satisfied through glycolytic pathways 
rather than the more efficient oxidative phosphorylation 
route known as the Warburg Effect.74,75 Additionally, the 
high interstitial pressure prevents clearance of metabolic 
end-products such as lactic acid. Enhanced hypoxia further 
leads to the up-regulation of growth factors such as platelet-
derived growth factor B (PDGF-B), transforming growth 
factor ß (TGF-ß), insulin-like growth factor 2 (IGF-2) and 
epidermal growth factor (EGF).76 Angiogenesis is regarded 
as the key contributor of metabolites and oxygen found 
in large tumours, thus allowing tumour progression.73 An 
additional prevailing mechanism thought to be involved in 
chemo-resistance is autophagy.
Autophagy
As mentioned previously, autophagy is characterised by the 
development of autophagosomes that engulf organelles and 
other cellular components such as proteins before fusing 
with the lysosome, which result in mass proteolysis. This 
has been shown to occur mainly in response to nutrient 
starvation, hypoxia, ATP depletion or signals prompting 
cellular remodelling and is mainly controlled via the mTOR 
signalling cascade. The current hypothesis in the literature 
reveals that autophagy might more accurately be described 
as a cell survival mechanism that acts alongside cell death 
but does not necessarily lead to it. Although cell death 
through autophagy has been suggested as a mechanism 
of tumour cell survival,77-78 it still remains a controversial 
matter whether autophagy leads to tumour formation or 
suppression. In addition, a study by Zhang and co-workers79 
revealed that hypoxia induces mitochondrial autophagy to 
prevent an increase in the level of reactive oxygen species 
and subsequent cell death. Thus, when viewed dynamically, 
it is becoming apparent that autophagy acts to delay cell 
death and may only lead to it in a last desperate effort while 
attempting to keep cells alive. However, this can only occur 
once autophagy has progressed and persisted beyond the 
so-called ‘point of no return’ (PONR), resulting in apoptosis 
or possibly even necrosis.80 There is, however, a great lack 
of knowledge regarding the progression of autophagy 
with time in oxygen and nutrient deficient tumour micro-
environments. This could be due to autophagy being 
recognised predominantly as a death mechanism in the 
cancer environment as well as due to the lack of investigation 
on autophagy in the different tumour micro-environments. 
This lack of knowledge raises areas of concern and questions 
which require clear answers: What is the specific role of 
autophagy in tumours and what is the contribution of 
autophagy to cellular survival during therapy? Whether cell 
death through autophagy or autophagy itself actually occurs 
in breast cancer is still largely undetermined, therefore 
further investigation in this field is required. Another 
concept that still remains to be explored is the possibility 
that malignant cells in the advanced stages of carcinogenesis 
undergo autophagy as a pro-survival mechanism.
Nutrient deprivation and autophagy
Since ancient times therapeutic fasting has been practiced as 
a method of healing in various health conditions. It appears 
that the body’s innate response against disease and infection 
is to limit its nutritional intake. Since such a phenomenon 
exists, the concept of controlled nutrient starvation is 
increasingly becoming an appealing concept worth exploring 
by physiologists and oncologists.
One of the earliest studies on therapeutic starvation was 
conducted in 1988 by Raffaghello and co-workers;81 normal 
and cancerous yeast cells were starved and then exposed 
to chemotherapy. They found that normal cells survived 
the toxic dosage but the cancer cells did not. This inspired 
an animal trial in which tumour bearing mice were starved 
for 48 hours after which a high dose of chemotherapy was 
administered. This study proved to be successful as 43% 
of the non-starved mice died, but only one of the starved 
mice. Once chemotherapy was terminated, a normal diet 
was resumed and the starved mice regained all the lost 
weight. With the great success of the animal trial, Raffaghello 
and co-workers82 proceeded with a human trial in 2010, in 
which ten patients starved for 48 to 140 hours prior to and 
5 to 56 hours after chemotherapy reported reduced side-
effects of the toxic drug.
It is known that cancer cells alter metabolism to suit 
their specific growth requirements and express chronic 
proliferation and thus require an increased need for energy 
and carbon/nitrogen sources for biomass production. As 
a major contributor to energy substrates during stressful 
conditions, autophagy supports cancer cells to meet their 
enhanced metabolic demands. The role that autophagy plays 
in cancer metabolism remains to be elucidated completely. 
Not much is known about how autophagy selectively 
accesses major energy sources such as amino acids, lipids and 
carbohydrates, and to what extent these sources contribute 
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to survival of cancer cells during stressful conditions such as 
hypoxia and nutrient deprivation. Therefore, one of the aims 
of our study was to determine whether the manipulation of 
autophagy can sensitise cancer cells to chemotherapy and 
protect normal cells against its detrimental side-effects.
The manipulation of autophagy increases 
the efficacy of the chemotherapeutic agent 
doxorubicin in cancer cells
Understanding how cancer cells are able to avoid and 
tolerate the effects of short-term starvation of nutrient 
supply could prove vital if future anticancer strategies are 
to be successfully developed based on this premise. Indeed, 
current research has already begun to investigate these 
avenues, and the recent employment of controlled starvation 
of cancer patients has exposed a potentially feasible and 
reproducible therapeutic approach. In a series of studies, we 
investigated the ability of a commonly used cancer cell line 
(MDAMB231), compared to a non-tumourigenic control 
line (MCF12A), to tolerate a short-term bout of nutrient 
restriction. Using this model, additional experiments were 
designed to provide mechanistic insight into these initial 
findings. Using this knowledge, studies were conducted 
in an attempt to exploit the novel anticancer potential of 
using nutrient starvation in conjunction with chemotherapy 
in vitro. A new and innovative cancer model was then 
developed to expand these findings into the in vivo setting. 
Initial experiments established that a fast growing, metastatic 
cancer cell line (MDAMB231) was more sensitive to amino 
acid starvation than a non-tumourigenic line (MCF12A). 
It was shown that short-term deprivation of amino acids 
resulted in increased cell death and a proliferation arrest in 
the cancer cells. Most cells are known to possess proficient 
intracellular mechanisms that are able to maintain amino 
acid levels during times of starvation. The up-regulation of 
autophagy through the autophagosomal-lysosomal pathway 
has been implicated as a mechanism used by cancer 
cells to maintain cellular ATP levels during nutrient-poor 
conditions. Normally autophagy functions as a cytoplasmic 
quality control mechanism to remove protein aggregates 
and damaged organelles. Recently published findings have 
revealed that human cancers with mutations in H-ras or 
K-ras may require autophagy for tumour survival and 
sustained growth.83 Although these mutations are not 
common in breast cancer, genetic modifications in regions 
coding for proteins elsewhere in the RAS pathway results 
in high RAS activation in a large percentage of breast 
malignancies. As the MDAMB231 breast cancer cell line is 
a known K-ras mutant, it was speculated that autophagy is 
crucial for this tolerance to acute nutrient starvation.83
Experimental evidence demonstrated that autophagy 
inhibition resulted in decreased cell survival and reduced 
proliferation levels during acute nutrient starvation in the 
MDAMB231 cell line. After a few hours without exposure 
to nutrients, protection was lost and intracellular cell death 
programmes initiated. Surprisingly, the slower growing, non-
cancer cell line was more tolerant to these periods of short-
term starvation. Autophagy frequently has been implicated 
as a potential survival mechanism in malignant tumours, 
based on the premise that the degradation products 
released following autophagy-mediated breakdown of 
cytoplasmic materials can be utilised for protein synthesis 
or as substrates for ATP production. Unfortunately, there is 
little direct evidence to support this hypothesis in cancer 
cells. Based on evidence from our previous experiments, 
the next study attempted to provide a rare insight into 
the autophagy-mediated changes in amino acid levels that 
occur during a short-term starvation event. We further 
supply some mechanistic support to explain the finding that 
autophagy protects MDAMB231 (cancer) and MCF12A 
(normal) cells during amino acid starvation. Unlike most 
existing studies into this phenomenon, the model design 
used here allowed for the delineation of the impact of 
amino acid starvation alone (a known trigger for increased 
autophagy) while all other nutrients remained constant. 
It was successfully demonstrated, by inhibiting autophagy 
pharmacologically (bafilomycin A1) or biologically (ATG5 
siRNA), that autophagy is a vital process for increasing 
tolerance to nutrient deprivation. Interestingly, it was 
shown that both cell lines utilised in these studies exhibited 
a short-lived autophagy-mediated surge in amino acid 
levels. While amino acid levels quickly decreased in the 
MDAMB231 cancer cells afterwards, presumably due to 
the high metabolic and biosynthesis needs of these cells, 
they remained elevated in the slower growing MCF12A 
normal cells. As autophagy inhibition blunted this protective 
response, it was inferred that generation of amino acids by 
autophagy is a vital mechanism during adaptive tolerance 
to short-term amino acid starvation. The discovery of an 
analogous elevation in free fatty acid levels during similar 
conditions (which could be blunted by autophagy inhibition) 
strengthened the hypothesis that increased autophagy 
results in the increased intracellular availability of basic 
protein and organelle constituents for reuse elsewhere 
in the cell. In an attempt to understand how these basic 
cellular building blocks were utilised by the cell, changes in 
ATP levels were examined during starvation in the presence 
or absence of autophagy inhibition. Surprisingly, autophagy-
related processes were implicated in the maintenance of 
ATP levels within these cell lines during nutrient starvation. 
MDAMB231 cells were revealed to be particularly reliant 
on the ATP homeostasis conferred by increased autophagy 
during the first hours of amino acid deprivation. Together, 
these three studies demonstrated how a cancer cell line 
that depends on autophagy for survival is able to avoid 
cell death during short-term starvation by generating 
basic cellular building blocks and utilising them for cellular 
processes such as ATP maintenance.
Many clinical trials are beginning to assess the effectiveness 
of compounds known to regulate autophagy in patients 
receiving anticancer therapy. As mentioned earlier, short-
term starvation has shown promise in alleviating some 
of the symptoms associated with chemotherapy. Our 
previous results demonstrated that nutrient deprivation 
elicited specific and dynamic alterations to autophagy in 
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MDAMB231 (cancer) cells. Using this data as a platform, we 
established that increased autophagy, associated with amino 
acid starvation in these cells, correlated with decreased cell 
survival during DXR treatment. Interestingly, a sustained 
elevation of autophagy in MCF12A cells (normal breast 
epithelial cells) during similar treatment was associated 
with protection from cell death during DXR treatment. As 
our data showed that a non-cancer cell line was protected 
if starved of amino acids during DXR treatment, while a 
cancer cell line with high basal autophagy activity had 
increased cell death, the next aim of this study was to verify 
this in an in vivo model.
Typically much of the solid tumour is made up of a variety 
of cell subpopulations that are required for continued 
growth and invasion. As these heterogeneous neoplasms 
are comprised of cancer and stromal elements, it is 
therefore essential that in vitro studies are translated in 
vivo. The next study was successful in establishing a novel 
mammary tumour model in a GFP-LC3 transgenic mouse. A 
reproducible method to study autophagy in the non-cancer 
subpopulation of tumours was established for the first 
time. The final study was undertaken in order to establish 
if tumours are protected or display decreased survival if 
basal autophagy flux is up-regulated (through amino acid 
starvation or rapamycin treatment) in mice during DXR 
treatment. Our results demonstrated that rapamycin 
treatment of mice receiving a high cumulative dose of 
DXR treatment increases animal survival. Furthermore, the 
combination treatment was just as effective as DXR alone 
to decrease tumour size in these animals.
The manipulation of autophagy attenuates 
doxorubicin-induced cardiotoxicity
As mentioned previously, the therapeutic potential of the 
chemotherapeutic agent DXR is restricted by its serious 
side-effects (cardiotoxicity) which can lead to congestive 
heart failure. Although numerous studies have attempted 
various methods to reduce anthracycline-induced 
cardiotoxicity, very few have been able to reproduce their 
results in a clinical setting. We have demonstrated that 
rapamycin, a potent inhibitor of the mTOR signalling pathway 
which induces autophagy, possesses cardioprotective effects 
against anthracycline-induced cardiotoxicity. 
We have demonstrated that DXR is a potent inducer 
of cell death, the ubiquitin-proteasome pathway (UPP), 
mitochondrial dysfunction and endoplasmic reticulum 
stress which are all attenuated by rapamycin (inducer of 
autophagy) treatment. Additionally, the co-treatment of 
rapamycin and DXR decreased cell death (apoptosis), 
increased cardiomyocyte size and prevented the decrease 
in body weight induced by DXR treatment in the in vivo 
model. Furthermore, as rapamycin is currently being 
used in the clinical setting to suppress tumour growth, 
its characteristics thus make this drug an ideal adjuvant 
therapy to either treat or prevent cardiotoxicity in order 
to potentially inhibit or delay heart failure.
We have demonstrated that autophagy protected cancer 
cells from the stressful microenvironment of hypoxia and 
starvation. Furthermore, cancer cells use autophagy to 
generate ATP during nutrient starvation. The amino acids 
generated through autophagy are utilised in the Krebs 
cycle to maintain ATP levels under nutrient starvation 
conditions. A further up-regulation of the already high basal 
autophagy levels sensitises cancer cells to DXR-induced 
cell death. In normal cells, including cardiomyocytes, DXR-
induced cytotoxicity is associated with reactive oxygen 
species (ROS) production, which leads to compromised 
mitochondrial function and morphology and eventually to 
cell death. Combination therapy of DXR and rapamycin 
improves cell viability in normal cells and attenuates 
apoptosis. Furthermore, it decreases ROS production 
and preserves mitochondrial function. It also prevents 
translocation of DXR into the nucleus, where it induces 
its cytotoxic actions. The model established by us, and the 
related findings, have presented a novel and unique platform 
for further research into this remarkable phenomenon, and 
particularly the role of autophagy in it.
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